159 related articles for article (PubMed ID: 36776648)
1. Serum Ustekinumab Concentrations Are Associated With Remission in Crohn's Disease Defined by a Serum-Based Endoscopic Healing Index.
Walshe M; Borowski K; Battat R; Hudesman D; Wolf DC; Okada L; Jain A; Silverberg MS
Crohns Colitis 360; 2021 Jul; 3(3):otab032. PubMed ID: 36776648
[TBL] [Abstract][Full Text] [Related]
2. Utility of Therapeutic Drug Monitoring for Tumor Necrosis Factor Antagonists and Ustekinumab in Postoperative Crohn's Disease.
Pan Y; Ahmed W; Mahtani P; Wong R; Longman R; Jeremy Lukin D; Scherl EJ; Battat R
Inflamm Bowel Dis; 2022 Dec; 28(12):1865-1871. PubMed ID: 35212368
[TBL] [Abstract][Full Text] [Related]
3. Ustekinumab trough concentration affects clinical and endoscopic outcomes in patients with refractory Crohn's disease: a Chinese real-world study.
Yao JY; Zhang M; Wang W; Peng X; Zhao JZ; Liu T; Li ZW; Sun HT; Hu P; Zhi M
BMC Gastroenterol; 2021 Oct; 21(1):380. PubMed ID: 34663208
[TBL] [Abstract][Full Text] [Related]
4. Ustekinumab Drug Levels and Outcomes in Inflammatory Bowel Disease.
Petrov J; Fine S; Alzahrani R; Mohamed G; Al-Bawardy B
J Clin Gastroenterol; 2024 Feb; ():. PubMed ID: 38300529
[TBL] [Abstract][Full Text] [Related]
5. Ustekinumab Tissue and Serum Levels in Patients With Crohn's Disease Are Closely Correlated Though Not Consistently Associated With Objective Response After Induction.
Proietti E; Pauwels RWM; van der Woude CJ; Doukas M; Oudijk L; Peppelenbosch MP; Grohmann U; Crombag MBS; de Vries AC; Fuhler GM
Inflamm Bowel Dis; 2023 Jul; 29(7):1038-1046. PubMed ID: 35917118
[TBL] [Abstract][Full Text] [Related]
6. Ustekinumab trough levels predicting laboratory and endoscopic remission in patients with Crohn's disease.
Hirayama H; Morita Y; Imai T; Takahashi K; Yoshida A; Bamba S; Inatomi O; Andoh A
BMC Gastroenterol; 2022 Apr; 22(1):195. PubMed ID: 35448957
[TBL] [Abstract][Full Text] [Related]
7. Ustekinumab Trough Concentrations Are Associated with Biochemical Outcomes in Patients with Crohn's Disease.
Straatmijer T; Biemans VBC; Moes DJAR; Hoentjen F; Ter Heine R; Maljaars PWJ; Theeuwen R; Pierik M; Duijvestein M; van der Meulen-de Jong AE;
Dig Dis Sci; 2023 Jun; 68(6):2647-2657. PubMed ID: 36920666
[TBL] [Abstract][Full Text] [Related]
8. The Relationship Between the Endoscopic Healing Index, Fecal Calprotectin, and Magnetic Resonance Enterography in Crohn's Disease.
Smith ES; Chen J; Pan Y; Mahtani P; Lukin D; Ahmed W; Longman R; Burakoff R; Scherl E; Battat R
J Clin Gastroenterol; 2024 Jul; 58(6):607-613. PubMed ID: 37646564
[TBL] [Abstract][Full Text] [Related]
9. Association Between Vedolizumab Levels, Anti-vedolizumab Antibodies, and Endoscopic Healing Index in a Large Population of Patients with Inflammatory Bowel Diseases.
Yarur AJ; Deepak P; Vande Casteele N; Battat R; Jain A; Okada L; Osterman M; Regueiro M
Dig Dis Sci; 2021 Oct; 66(10):3563-3569. PubMed ID: 33089483
[TBL] [Abstract][Full Text] [Related]
10. Association between ustekinumab trough concentrations and biochemical outcomes in patients with Crohn's disease. A real life study.
Gómez Espín R; Nicolás De Prado I; Gil Candel M; González Carrión M; Rentero Redondo L; Iniesta Navalón C
Rev Esp Enferm Dig; 2021 Feb; 113(2):110-115. PubMed ID: 33213170
[TBL] [Abstract][Full Text] [Related]
11. Ustekinumab Serum Trough Levels May Identify Suboptimal Responders to Ustekinumab in Crohn's Disease.
Painchart C; Brabant S; Duveau N; Nachury M; Desreumaux P; Branche J; Gérard R; Prevost CLD; Wils P; Lambin T; Boualit M; Labalette M; Pariente B
Dig Dis Sci; 2020 May; 65(5):1445-1452. PubMed ID: 31599389
[TBL] [Abstract][Full Text] [Related]
12. Predictive models assessing the response to ustekinumab highlight the value of therapeutic drug monitoring in Crohn's disease.
Liefferinckx C; Hubert A; Thomas D; Bottieau J; Minsart C; Cremer A; Amininejad L; Vallée F; Toubeau JF; Franchimont D
Dig Liver Dis; 2023 Mar; 55(3):366-372. PubMed ID: 35977875
[TBL] [Abstract][Full Text] [Related]
13. Ustekinumab for Crohn's disease: a nationwide real-life cohort study from Finland (FINUSTE).
Eberl A; Hallinen T; Af Björkesten CG; Heikkinen M; Hirsi E; Kellokumpu M; Koskinen I; Moilanen V; Nielsen C; Nuutinen H; Suhonen UM; Utriainen K; Vihriälä I; Soini E; Wennerström C; Nissinen R; Borsi A; Koivunen M; Tillonen J; Sipponen T
Scand J Gastroenterol; 2019 Jun; 54(6):718-725. PubMed ID: 31184512
[No Abstract] [Full Text] [Related]
14. Feasibility of a Clinical Decision Support Tool for Ustekinumab to Predict Clinical Remission and Relapse in Patients With Crohn's Disease: A Multicenter Observational Study.
Park J; Chun J; Yoon H; Cheon JH
Inflamm Bowel Dis; 2023 Apr; 29(4):548-554. PubMed ID: 35670522
[TBL] [Abstract][Full Text] [Related]
15. Utility of the Serum-Based Endoscopic Healing Index in Monitoring Therapeutic Response in Ulcerative Colitis.
Alsoud D; Ho J; Sabino J; Ferrante M; Vermeire S; Verstockt B
Am J Gastroenterol; 2024 Mar; 119(3):477-485. PubMed ID: 37753938
[TBL] [Abstract][Full Text] [Related]
16. Real-world Endoscopic and Histological Outcomes Are Correlated with Ustekinumab Exposure in Patients with Ulcerative Colitis.
Alsoud D; De Hertogh G; Compernolle G; Tops S; Sabino J; Ferrante M; Thomas D; Vermeire S; Verstockt B
J Crohns Colitis; 2022 Nov; 16(10):1562-1570. PubMed ID: 35533353
[TBL] [Abstract][Full Text] [Related]
17. Dual-Targeted Therapy with Upadacitinib and Ustekinumab in Medically Complex Crohn's Disease.
Miyatani Y; Choi D; Choi NK; Rubin DT
Dig Dis Sci; 2024 Feb; 69(2):355-359. PubMed ID: 38112840
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Intravenous Ustekinumab Reinduction in Patients With Crohn's Disease With a Loss of Response.
Heron V; Li Fraine S; Panaccione N; Restellini S; Germain P; Candido K; Bernstein CN; Bessissow T; Bitton A; Chauhan UK; Lakatos PL; Marshall JK; Michetti P; Seow CH; Rosenfeld G; Panaccione R; Afif W
J Can Assoc Gastroenterol; 2022 Oct; 5(5):208-213. PubMed ID: 36196277
[TBL] [Abstract][Full Text] [Related]
19. Noninvasive Targeted Crohn Disease Management by Combining Endoscopic Healing Index and Therapeutic Drug Monitoring.
Hemperly A; Dubinsky MC; Yarur A; Afzali A; Hanauer S; Kugathasan S; Long MD; Rabizadeh S; Sockolow R; Okada L; Jain A; Abreu MT; Vande Casteele N
Crohns Colitis 360; 2021 Jul; 3(3):otab035. PubMed ID: 36776644
[TBL] [Abstract][Full Text] [Related]
20. Ustekinumab in pediatric patients with Crohn's disease: safety, and efficacy results from a multicenter retrospective study in China.
Li P; Wang L; Tang Z; Wang Y; Liu Z; Ge W; Huang Y
Front Pediatr; 2024; 12():1371322. PubMed ID: 38665375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]